Harvard Bioscience, Inc. (HBIO)
NASDAQ: HBIO · Real-Time Price · USD
2.270
+0.110 (5.09%)
Nov 22, 2024, 4:00 PM EST - Market closed
Harvard Bioscience Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 97.73 | 112.25 | 113.34 | 118.9 | 102.1 | 116.18 | Upgrade
|
| Revenue Growth (YoY) | -13.15% | -0.96% | -4.68% | 16.46% | -12.12% | -3.81% | Upgrade
|
| Cost of Revenue | 40.33 | 45.86 | 51.05 | 51.25 | 44.06 | 51.62 | Upgrade
|
| Gross Profit | 57.4 | 66.39 | 62.29 | 67.65 | 58.04 | 64.56 | Upgrade
|
| Selling, General & Admin | 44.73 | 46.61 | 49.03 | 47.32 | 41.39 | 46.02 | Upgrade
|
| Research & Development | 11.23 | 11.76 | 12.33 | 10.8 | 8.69 | 10.72 | Upgrade
|
| Operating Expenses | 61.69 | 63.9 | 67.48 | 63.96 | 55.79 | 62.49 | Upgrade
|
| Operating Income | -4.29 | 2.5 | -5.19 | 3.69 | 2.25 | 2.07 | Upgrade
|
| Interest Expense | -3.15 | -3.59 | -2.55 | -1.54 | -4.83 | -5.41 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | - | -0.5 | -0.1 | Upgrade
|
| Other Non Operating Income (Expenses) | -2.23 | -0.44 | 0.72 | -1.02 | -0.31 | -0.37 | Upgrade
|
| EBT Excluding Unusual Items | -10.89 | -1.53 | -7.02 | 1.14 | -3.38 | -3.81 | Upgrade
|
| Merger & Restructuring Charges | -0.97 | -0.39 | -2.39 | -1.28 | -2.03 | -0.7 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.63 | -0.63 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.4 | - | - | - | - | - | Upgrade
|
| Asset Writedown | - | - | - | - | - | -1 | Upgrade
|
| Legal Settlements | - | - | 0.23 | - | - | - | Upgrade
|
| Other Unusual Items | -0.47 | - | - | - | -1.88 | - | Upgrade
|
| Pretax Income | -13.36 | -2.56 | -9.18 | -0.14 | -7.29 | -5.5 | Upgrade
|
| Income Tax Expense | 0.88 | 0.86 | 0.34 | 0.15 | 0.52 | -0.82 | Upgrade
|
| Earnings From Continuing Operations | -14.24 | -3.42 | -9.52 | -0.29 | -7.81 | -4.69 | Upgrade
|
| Net Income | -14.24 | -3.42 | -9.52 | -0.29 | -7.81 | -4.69 | Upgrade
|
| Net Income to Common | -14.24 | -3.42 | -9.52 | -0.29 | -7.81 | -4.69 | Upgrade
|
| Shares Outstanding (Basic) | 43 | 42 | 41 | 40 | 39 | 38 | Upgrade
|
| Shares Outstanding (Diluted) | 43 | 42 | 41 | 40 | 39 | 38 | Upgrade
|
| Shares Change (YoY) | 2.68% | 2.43% | 2.65% | 4.41% | 2.19% | 3.73% | Upgrade
|
| EPS (Basic) | -0.33 | -0.08 | -0.23 | -0.01 | -0.20 | -0.12 | Upgrade
|
| EPS (Diluted) | -0.33 | -0.08 | -0.23 | -0.01 | -0.20 | -0.12 | Upgrade
|
| Free Cash Flow | 0.85 | 12.24 | -0.44 | 0.07 | 8.18 | 6.83 | Upgrade
|
| Free Cash Flow Per Share | 0.02 | 0.29 | -0.01 | 0.00 | 0.21 | 0.18 | Upgrade
|
| Gross Margin | 58.73% | 59.15% | 54.96% | 56.90% | 56.85% | 55.57% | Upgrade
|
| Operating Margin | -4.39% | 2.22% | -4.58% | 3.10% | 2.21% | 1.78% | Upgrade
|
| Profit Margin | -14.57% | -3.04% | -8.40% | -0.24% | -7.65% | -4.03% | Upgrade
|
| Free Cash Flow Margin | 0.86% | 10.90% | -0.39% | 0.06% | 8.01% | 5.88% | Upgrade
|
| EBITDA | 2.88 | 9.49 | 2.38 | 11.31 | 9.89 | 9.81 | Upgrade
|
| EBITDA Margin | 2.95% | 8.46% | 2.10% | 9.51% | 9.68% | 8.44% | Upgrade
|
| D&A For EBITDA | 7.17 | 7 | 7.58 | 7.62 | 7.63 | 7.73 | Upgrade
|
| EBIT | -4.29 | 2.5 | -5.19 | 3.69 | 2.25 | 2.07 | Upgrade
|
| EBIT Margin | -4.39% | 2.22% | -4.58% | 3.10% | 2.21% | 1.78% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.